---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-001050"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:53:26.191027+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Moleculin: MIRACLE trial unblinding on track for Q1 2026; global expansion to 9 countries

## Summary
- First unblinding of 45 subjects in pivotal Phase 2B/3 MIRACLE trial for 2L AML expected Q1 2026.
- Trial expanded to 9 countries with over 46 sites selected; next unblinding of 90 subjects expected Q3 2026.
- Atlantic Health to fund IIT with Annamycin in 3L pancreatic cancer; preclinical data show activity.
- WP1066 Phase 2 GBM trial at Northwestern continues; Emory to start pediatric brain tumor trial in 2H 2026.
- Non-cardiotoxicity review of Annamycin data to be presented Q1 2026; potential first non-cardiotoxic anthracycline.

## SEC filing metadata
- accession: 0001437749-26-001050
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926001050/0001437749-26-001050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926001050/mbrx20260110_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-001050
- JSON: https://secwatch.observer/filing/0001437749-26-001050.json
- Plain text: https://secwatch.observer/filing/0001437749-26-001050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.